You just read:

Boston Biomedical Initiates CanStem303C: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Pretreated Advanced Colorectal Cancer

News provided by

Boston Biomedical Pharma, Inc.

Oct 21, 2016, 08:00 ET